13-Nov-2024 6:00 AM CST - Business Wire MindMed to Participate in Upcoming Investor Conferences Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Companys management team will participate in the following investor conferences: Jefferies London Healthcare Conference Format: 1x1 Meetings Dates: November 20-21, 2024 Location: London, UK 7th Annual Evercore HealthCONx Conference Format: Fireside
7-Nov-2024 3:01 PM CST - Business Wire MindMed Reports Third Quarter 2024 Financial Results and Business Updates Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended September 30, 2024, and provided a business update. This is a pivotal moment for MindMed as we prepare to initiate Voyage, our first Phase 3 study of MM120 ODT in GAD, said Rob Barrow, Chief Executive Officer of MindMed. B
24-Oct-2024 6:00 AM CST - Business Wire MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Companys results for the third quarter ended September 30, 2024. Listeners can register for the webcast via this link. Analysts wishing t
13-Nov-2024 6:00 AM CST - Business Wire MindMed to Participate in Upcoming Investor Conferences Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Companys management team will participate in the following investor conferences: Jefferies London Healthcare Conference Format: 1x1 Meetings Dates: November 20-21, 2024 Location: London, UK 7th Annual Evercore HealthCONx Conference Format: Fireside
7-Nov-2024 3:01 PM CST - Business Wire MindMed Reports Third Quarter 2024 Financial Results and Business Updates Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended September 30, 2024, and provided a business update. This is a pivotal moment for MindMed as we prepare to initiate Voyage, our first Phase 3 study of MM120 ODT in GAD, said Rob Barrow, Chief Executive Officer of MindMed. B
24-Oct-2024 6:00 AM CST - Business Wire MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the Company or MindMed), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Companys results for the third quarter ended September 30, 2024. Listeners can register for the webcast via this link. Analysts wishing t
